Keywords: Hypertension, Telmisartan, Amlodipine, Valsartan, Novartis, Market, USA, Europe, Fixed-dose combinations

Fixed-dose combo of telmisartan/amlodipine “will become clinical gold standard for hypertension” in 2013

Article | 8 January 2010

• Print This

A hypertension drug that requires less-frequent dosing than Novartis's Diovan/Tareg (valsartan) would earn 30% patient share according to surveyed US cardiologists. Similarly, in Europe, such an agent would earn comparable patient share of 25% according to surveyed European cardiologists. These patient shares are significantly higher than Diovan/Tareg's current patient share (6.1%) and are higher than the patient share achieved by any current hypertension drug, states a new report from Decision Resources.

"In the crowded hypertension market, 25% to 30% patient shares are unlikely reached without any evidence of long-term clinical benefit. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.